SpyGlass Pharma Inc · Q2 2026 earnings

Briefing

SpyGlass Pharma Inc reported a net loss of $19.9 million for Q2 2026 as it advanced Phase 3 trials for its lead product candidate.

The late-stage biopharmaceutical company continued development of its BIM-IOL System with two registrational Phase 3 trials underway. Operating expenses rose sharply to $22.0 million driven by increased R&D and G&A spending following its February 2026 IPO. The company ended the quarter with $223.1 million in cash and cash equivalents to fund operations through 2028.

• Net loss increased to $19.9 million from $8.7 million in Q2 2025 due to higher operating expenses
• R&D expenses grew 49% year-over-year to $10.9 million while G&A expenses increased to $11.0 million
• Cash and cash equivalents reached $223.1 million following the $172.5 million IPO completed in February 2026
• Phase 3 enrollment expected to complete in 2027 with NDA submission planned for 2028 pending positive results

Headline financials